Braveheart Bio, Inc. (BRVE) vs Omeros Corporation (OMER)

A side-by-side comparison of Braveheart Bio, Inc. and Omeros Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BRVE

Braveheart Bio, Inc.

$1.41B

$19.92HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT

OMER

Omeros Corporation

$1.34B

$18.53HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT

Total return — BRVE vs OMER

growth of $100 · dividends reinvested · last 1y

BRVE +18.6% (+18.6%/yr)OMER +49.4% (+49.4%/yr)OMER compounded faster over this window

BRVE OMER

Metrics side by side

Total return (annualized)

Metric	BRVE	OMER
Total return (1Y)	N/A	309.88%
Total return CAGR (3Y)	N/A	90.10%
Total return CAGR (5Y)	N/A	21.70%
Total return CAGR (10Y)	N/A	6.50%

BRVE is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full BRVE analysis Full OMER analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.